Severity: Warning
Message: Undefined array key "articleIDUniqueCode"
Filename: frontend/article.php
Line Number: 189
Severity: 8192
Message: substr(): Passing null to parameter #1 ($string) of type string is deprecated
Filename: frontend/article.php
Line Number: 189
Severity: Warning
Message: Undefined array key "articleIDUniqueCode"
Filename: frontend/article.php
Line Number: 190
Severity: 8192
Message: substr(): Passing null to parameter #1 ($string) of type string is deprecated
Filename: frontend/article.php
Line Number: 190
Severity: Warning
Message: Undefined array key "articleIDUniqueCode"
Filename: frontend/article.php
Line Number: 213
Severity: 8192
Message: substr(): Passing null to parameter #1 ($string) of type string is deprecated
Filename: frontend/article.php
Line Number: 213
Severity: Warning
Message: Undefined array key "articleIDUniqueCode"
Filename: frontend/article.php
Line Number: 214
Severity: 8192
Message: substr(): Passing null to parameter #1 ($string) of type string is deprecated
Filename: frontend/article.php
Line Number: 214
We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Severity: Warning
Message: Undefined array key "articleIDUniqueCode"
Filename: frontend/article.php
Line Number: 424
Dr. N. J. Paulbudhe College of Pharmacy, Ahilyanagar
Cyclophosphamide (CTX) is an alkylating cytotoxic agent that primarily targets proliferating lymphocytes. It has been widely used as a chemotherapeutic and disease-modifying agent against several malignancies, lymphomas, and some autoimmune diseases. Depending on the dose and timing of administration, CTX can also improve immune responses. Although the hypothesized mechanism of tumor specificity (activation by cancer cell phosphamidases) turned out to be irrelevant to its activity, it was initially created to selectively target cancer cells. Nonetheless, cyclophosphamide's distinct cytotoxic properties are attributable to its unique metabolism and inactivation by aldehyde dehydrogenase. This review was conducted to identify cyclophosphamide-related toxicities as reported in prior research on that topic. Ninety-one articles were obtained, but only six studies met the inclusion criteria. The studies included a total of 3,531 participants. Cyclophosphamide was linked to a number of toxicities, including liver toxicity, urotoxicity, cardiac toxicity, hematological, and non-hematological toxicities. The toxicity of cyclophosphamide varied depending on the regimen and combination drugs, as well as some gene variants.
Cyclophosphamide (CTX) belongs to a class of cytotoxic alkylating nitrogen mustard chemicals, and is also marketed under the trade names ENDOXAN®, CYTOXAN®, ROCYTOX®, and NEOSAR®. The amount of CTX given in animal models and in humans varies according on the treatment objective and plan. Due to its selective cytotoxicity on lymphocytes without being myeloablative, high-dose CTX therapy (≥200 mg/kg) was originally developed as a conditioning regimen for allogeneic bone marrow transplantation to prevent graft-versus-host disease (GvHD).[1] One of the greatest anti-cancer medications ever created is cyclophosphamide. Even fifty years after its invention, it is still widely used in chemotherapy and in the conditioning and mobilization procedures for blood and marrow transplantation (BMT). Cyclophosphamide was found to be the most effective molecule after testing 1,000 chosen compounds and antibiotics against 33 tumors. In 1958, the first clinical trials of cyclophosphamide for the treatment of cancer were carried out, and in 1959, the FDA authorized it as the eighth cytotoxic anticancer drug. [6]
Mohalkar Krushna*, Dahatonde Abhijit, Munfan Sumit, Dr. Tarde Vijay, Beyond Alkylation ? Cyclophosphamide?s Expanding Role in Cancer Therapy and Immunomodulation, Int. J. Sci. R. Tech., 2025, 2 (11), 636-646. https://doi.org/10.5281/zenodo.17682329
10.5281/zenodo.17682329